{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T08:48:04Z","timestamp":1745484484190},"reference-count":9,"publisher":"Tsinghua University Press","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.26599\/1671-5411.2024.07.006","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T02:08:06Z","timestamp":1724638086000},"page":"713-715","source":"Crossref","is-referenced-by-count":1,"title":["Interpretation of Chinese Expert Consensus on the Diagnosis and Management Strategy of Patients with Statin Intolerance: A guiding file for helping to lipid management for Chinese population"],"prefix":"10.26599","volume":"21","author":[{"given":"Jian-Jun","family":"LI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11138","reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12933-022-01551-3","article-title":"Landscape of cardiometabolic risk factors in Chinese population: a narrative review","volume":"21","author":"JJ Li","year":"2022","unstructured":"JJ Li. Landscape of cardiometabolic risk factors in Chinese population: a narrative review. 2022, 21: 113.","journal-title":"Cardiovasc Diabetol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.31083\/j.rcm2412373","article-title":"Landscape of statin as a cornerstone in atherosclerotic cardiovascular disease","volume":"24","author":"C Yang","year":"2023","unstructured":"C Yang. Landscape of statin as a cornerstone in atherosclerotic cardiovascular disease. 2023, 24: 373.","journal-title":"Rev Cardiovsc Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","article-title":"2023 Chinese guidelines for lipid management","volume":"14","author":"J-J Li","year":"2023","unstructured":"J-J Li. 2023 Chinese guidelines for lipid management. 2023, 14: 1190934.","journal-title":"Front Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient","volume":"16","author":"MK Cheeley","year":"2022","unstructured":"MK Cheeley. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. 2022, 16: 361-375.","journal-title":"J Clin Lipidol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.jfma.2018.11.017","article-title":"2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance","volume":"118","author":"SC Chien","year":"2019","unstructured":"SC Chien. 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance. 2019, 118: 1385-1392.","journal-title":"J Formos Med Assoc"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.5551\/jat.50948","article-title":"Statin intolerance clinical guide 2018","volume":"27","author":"K Kajinami","year":"2020","unstructured":"K Kajinami. Statin intolerance clinical guide 2018. 2020, 27: 375-396.","journal-title":"J Atheroscler Thromb"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2016.01.003","author":"","unstructured":"","journal-title":"null"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/17425255.2020.1802426","article-title":"Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects","volume":"16","author":"JJ Li","year":"2020","unstructured":"JJ Li. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. 2020, 16: 837-851.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2217\/clp.12.90","article-title":"Comparative study of high-dose Xuezhikang and low-dose Xuezhikang plus Ezetimibe on pro- and anti-inflammatory markers","volume":"8","author":"J Liu","year":"2013","unstructured":"J Liu. Comparative study of high-dose Xuezhikang and low-dose Xuezhikang plus Ezetimibe on pro- and anti-inflammatory markers. 2013, 8: 151-157.","journal-title":"Clin Lipidol"}],"container-title":["Journal of Geriatric Cardiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T02:08:09Z","timestamp":1724638089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciopen.com\/article\/10.26599\/1671-5411.2024.07.006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"URL":"https:\/\/doi.org\/10.26599\/1671-5411.2024.07.006","relation":{},"ISSN":["1671-5411"],"issn-type":[{"value":"1671-5411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}